Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting

7 months ago 22
Read Entire Article
  1. Homepage
  2. Finance
  3. Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting

Related

Sobi to acquire Arthrosi Therapeutics for $950 million

Sobi to acquire Arthrosi Therapeutics for $950 million

2 hours ago 1
Engine failure forces United Airlines flight to return to DC-area airport

Engine failure forces United Airlines flight to return to DC...

3 hours ago 3
Prosecutors need warrant to access files from dismissed Comey case, judge rules

Prosecutors need warrant to access files from dismissed Come...

5 hours ago 3

Trending

Popular

College football by the odds: Vegas picks and preview of Ohio State vs. Notre Dame

College football by the odds: Vegas picks and preview of Ohi...

10 months ago 631
What is Tren de Aragua, the Venezuelan gang targeted by Trump?

What is Tren de Aragua, the Venezuelan gang targeted by Trum...

8 months ago 499
Taiwan slightly cuts 2025 GDP growth outlook amid Trump tariffs concern

Taiwan slightly cuts 2025 GDP growth outlook amid Trump tari...

9 months ago 366
Australian whose blood saved 2.4 million babies dies

Australian whose blood saved 2.4 million babies dies

9 months ago 324
What to do in Las Vegas this week: January 2-8

What to do in Las Vegas this week: January 2-8

11 months ago 318
English (US) English (US) ·
About Us · Contact Us · Terms & Conditions ·

© Sincity Press 2025. All rights are reserved